

Tina-quant β 2-Microglobulin (serum/plasma application)**Order information**

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used	
08047499 190	Tina-quant β 2-Microglobulin (140 tests)	System-ID 01 6864 2	Roche/Hitachi cobas c 701/702
Materials required (but not provided):			
08047545 190	Calibrator β 2-Microglobulin	Code 474	
08362785 190	Control Set β 2-Microglobulin	Level I: Code 144 Level II: Code 145	
05172152 190	Diluent NaCl 9 % (119 mL)	System-ID 08 6869 3	

English**System information**For **cobas c** 701/702 analyzers:**B2MGS:** ACN 8093**Intended use**

Immunoturbidimetric assay for the quantitative in vitro determination of β 2-microglobulin (B2MG) in human serum and plasma on Roche/Hitachi **cobas c** systems.

Summary

B2MG is a low-molecular-weight protein with approximately 12 kDa. It is identical to the light chain of the major histocompatibility complex (MHC) antigens (HLA, A, B, C). Thus B2MG is expressed on the cell membrane of nearly all nucleated cells (exception: trophoblasts).^{1,2} Lymphocytes are the major location of synthesis. B2MG is constantly released into the blood in small quantities. Due to its low molecular weight, it is rapidly filtered through the renal glomeruli. Thereafter, up to 99.9 % is reabsorbed by the proximal tubules.³

B2MG serum concentrations are increased in autoimmune diseases, inflammation, in liver disease, in some malignancies such as myeloma, and in neoplasms. Furthermore, patients with renal failure have a large increase in circulating serum levels because glomerular filtration is the primary clearance mechanism.^{4,5}

B2MG clearance during dialysis treatment is clinically significant since B2MG can deposit as amyloid, leading to systemic amyloidosis in many patients on long-term dialysis.⁴

Various assay methods are available for B2MG determination, such as radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), nephelometric immunoassays, and turbidimetric methods.² The Roche B2MG assay is based on the principle of immunological agglutination with latex reaction enhancement.

Test principle

Immunoturbidimetric assay.

Latex-bound anti- β 2-microglobulin antibodies react with antigen from the sample to form antigen/antibody complexes which are determined turbidimetrically after agglutination.⁶

Reagents - working solutions

R1	TRIS/HCl buffer: 23 g/L, pH 8.2; NaCl: 19 g/L; EDTA: 1.3 g/L; preservative
R3	Latex particles coated with polyclonal anti-human β 2-microglobulin antibody (rabbit): 1.9 g/L; preservative

R1 is in position B and R3 is in position C.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

Reagent handling

Ready for use

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

Storage and stability**B2MG**

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

On-board on the Reagent Manager: 24 hours

Diluent NaCl 9 %

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label

On-board in use and refrigerated on the analyzer: 4 weeks

On-board on the Reagent Manager: 24 hours

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum.

Plasma: Li-heparin, K₂- and K₃-EDTA plasma.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

Stability in serum and Li-heparin, 3 days at 15-25 °C

K₂- and K₃-EDTA plasma: 3 days at 2-8 °C

6 months at -20 ± 5 °C

Freezing and thawing up to 2 times is allowed.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma**cobas c 701/702 test definition**

Assay type	2 Point End
Reaction time / Assay points	10 / 24-34
Wavelength (sub/main)	-700 nm
Reaction direction	Increase
Units	mg/L (nmol/L)

Reagent pipetting		Diluent (H ₂ O)
R1	124 μ L	–
R3	124 μ L	–

<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	2 μ L	–	–
Decreased	2 μ L	10 μ L	100 μ L
Increased	2 μ L	–	–

Calibration

Calibrators	S1: H ₂ O S2: Calibrator β 2-Microglobulin
Calibration mode	Linear
Calibration frequency	2-point calibration - after reagent lot change - as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the WHO standard.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factor: mg/L x 84.7 = nmol/L

Limitations - interference

Criterion: Recovery within \pm 0.22 mg/L (18.6 nmol/L) of initial values at a β 2-microglobulin concentration of \leq 2.2 mg/L (186 nmol/L) and within \pm 10 % for samples $>$ 2.2 mg/L.

Icterus:⁷ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 μ mol/L or 60 mg/dL).

Hemolysis:⁷ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 μ mol/L or 1000 mg/dL).

Lipemia (Intralipid):⁷ No significant interference up to an L index of 1000. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

High dose hook-effect: No false result occurs up to a B2MG concentration of 240 mg/L (20328 nmol/L).

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{8,9}

Rheumatoid factors: No significant interference from rheumatoid factors up to a concentration of 1200 IU/mL.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹⁰

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is required in certain cases. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SmpCln1+2/SCCS Method Sheet and for further instructions refer to the operator's manual.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges**Measuring range**

0.2-8.0 mg/L (16.9-678 nmol/L)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:11 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 11.

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 0.1 mg/L (8.5 nmol/L)

Limit of Detection = 0.15 mg/L (12.7 nmol/L)

Limit of Quantitation = 0.2 mg/L (16.9 nmol/L)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 20 %. It has been determined using low concentration human β 2-microglobulin samples.

Expected values

$<$ 60 years 0.8-2.4 mg/L (68-203 nmol/L)²

$>$ 60 years \leq 3.0 mg/L (254 nmol/L)²

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Repeatability and intermediate precision were determined using human samples in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements (4 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Tina-quant β2-Microglobulin (serum/plasma application)

<i>Repeatability</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mg/L (nmol/L)</i>	<i>mg/L (nmol/L)</i>	<i>%</i>
Human serum 1	1.17 (99.1)	0.0109 (0.923)	0.9
Human serum 2	2.16 (183)	0.0140 (1.19)	0.6
Human serum 3	2.94 (249)	0.0195 (1.65)	0.7
Human serum 4	4.13 (350)	0.0234 (1.98)	0.6
Human serum 5	7.23 (612)	0.0321 (2.72)	0.4
<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mg/L (nmol/L)</i>	<i>mg/L (nmol/L)</i>	<i>%</i>
Human serum 1	1.17 (99.1)	0.0570 (4.83)	4.9
Human serum 2	2.16 (183)	0.0659 (5.58)	3.0
Human serum 3	2.94 (249)	0.0604 (5.12)	2.1
Human serum 4	4.13 (350)	0.0649 (5.50)	1.6
Human serum 5	7.23 (612)	0.255 (21.6)	3.5

Method comparison

β2-Microglobulin values for human serum samples obtained on a Roche/Hitachi **cobas c 701** analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi **cobas c 501** analyzer (x).

Sample size (n) = 65

Passing/Bablok ¹¹	Linear regression
$y = 0.954x + 0.005 \text{ mg/L}$	$y = 0.953x + 0.015 \text{ mg/L}$
$r = 0.964$	$r = 0.999$

The sample concentrations were between 1.10 and 7.48 mg/L (93.2 and 634 nmol/L).

References

- Kawata M, Parnes JR, Herzenberg LA. Transcriptional control of HLA-A,B,C antigen in human placental cytotrophoblast isolated using trophoblast- and HLA-specific monoclonal antibodies and the fluorescence-activated cell sorter. *J Exp Med* 1984 Sep;160(3):633-651.
- Thomas L. *Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results*. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft 1998;685-688.
- Stadius van Eps LW, Schardijn GH. Value of determination of beta2-microglobulin in toxic nephropathy and interstitial nephritis. *Wien Klin Wochenschr* 1984 Sep;96(18):673-678.
- Burtis CA, Ashwood ER, Bruns DE, eds. *Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics*, 7th ed. Elsevier Saunders 2015;306.
- Marshall WJ, Bangert SK (eds.). *Clinical Biochemistry: Metabolic and Clinical Aspects*. 2nd ed. Churchill Livingstone 2008;160-167.
- Bernard AM, Vyskocil A, Lauwerys RR. Determination of b2-Microglobulin in Human Urine and Serum by Latex Immunoassay. *Clin Chem* 1981;27(6):832-837.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". *Eur J Clin Chem Clin Biochem* 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. *Ann Clin Biochem* 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. *Clin Chem Lab Med* 2007;45(9):1240-1243.




- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS C and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2020, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

+800 5505 6606



Tina-quant β 2-Microglobulin (urine application)**Order information**

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used	
08047499 190	Tina-quant β 2-Microglobulin (140 tests)	System-ID 01 6864 2	Roche/Hitachi cobas c 701/702
Materials required (but not provided):			
08047545 190	Calibrator β 2-Microglobulin	Code 474	
08362785 190	Control Set β 2-Microglobulin	Level I: Code 144 Level II: Code 145	
05172152 190	Diluent NaCl 9 % (119 mL)	System-ID 08 6869 3	

English**System information**For **cobas c** 701/702 analyzers:**B2MGU**: ACN 8231**Intended use**

Immunoturbidimetric assay for the quantitative in vitro determination of β 2-microglobulin (B2MG) in human urine on Roche/Hitachi **cobas c** systems.

Summary

B2MG is a low-molecular-weight protein with approximately 12 kDa. It is identical to the light chain of the major histocompatibility complex (MHC) antigens (HLA, A, B, C). Thus B2MG is expressed on the cell membrane of nearly all nucleated cells (exception: trophoblasts).^{1,2} Lymphocytes are the major location of synthesis. B2MG is constantly released into the blood in small quantities. Due to its low molecular weight, it is rapidly filtered through the renal glomeruli. Thereafter, up to 99.9 % is reabsorbed by the proximal tubules.³

Drug nephrotoxicity causing severe, acute changes in tubular reabsorption and progressive renal diseases causing irreversible structural tubular defects impair tubular reabsorption of numerous smaller proteins including B2MG.⁴ Thus, urinary B2MG is discussed as a marker for the diagnosis and monitoring of tubulointerstitial renal damage.² Excretion of B2MG is increased in Fanconi syndrome, a generalized dysfunction of the proximal tubules. Causes for acquired Fanconi syndrome include exposure to toxins and drugs.⁵

Elevated B2MG values may identify patients at higher risk of glomerular filtration rate (GFR) decline in other kidney diseases such as membranous nephropathy.⁶ Furthermore, there is evidence that B2MG excretion is associated with acute allograft rejection in renal transplant recipients.⁷

Various assay methods are available for B2MG determination, such as radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), nephelometric immunoassays, and turbidimetric methods.² The Roche B2MG assay is based on the principle of immunological agglutination with latex reaction enhancement.

Test principle

Immunoturbidimetric assay.

Latex-bound anti- β 2-microglobulin antibodies react with antigen from the sample to form antigen/antibody complexes which are determined turbidimetrically after agglutination.⁸

Reagents - working solutions

- R1** TRIS/HCl buffer: 23 g/L, pH 8.2; NaCl: 19 g/L; EDTA: 1.3 g/L; preservative
- R3** Latex particles coated with polyclonal anti-human β 2-microglobulin antibody (rabbit): 1.9 g/L; preservative

R1 is in position B and R3 is in position C.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

Reagent handling

Ready for use

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

Storage and stability**B2MG**

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

On-board on the Reagent Manager: 24 hours

Diluent NaCl 9 %

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label

On-board in use and refrigerated on the analyzer: 4 weeks

On-board on the Reagent Manager: 24 hours

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Urine.

Each urine sample must be centrifuged (10 minutes at approximately 3000 x g) prior to testing.⁹

B2MG is unstable in acidic conditions and degradation occurs at pH < 6 within 2 hours.^{2,10} Thus, pre-analytical conditions are highly important. Since the degradation also takes place in the bladder, collection of a spot urine sample should not be performed in the morning due to a lower urine pH.²

A strict control of the urine pH after collection is required: urine samples must be adjusted to pH 7-9 by the addition of 1 N NaOH as soon as possible after receipt.¹⁰

Centrifuge samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the method sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

Stability in urine: 5 days at 15-25 °C
14 days at 2-8 °C
12 weeks at -20 ± 5 °C
Freezing and thawing up to 2 times is allowed.

Materials provided

See "Reagents – working solutions" section for reagents.

Tina-quant β 2-Microglobulin (urine application)**Materials required (but not provided)**

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for urine**cobas c 701/702 test definition**

Assay type	2 Point End		
Reaction time / Assay points	10 / 24-34		
Wavelength (sub/main)	-700 nm		
Reaction direction	Increase		
Units	mg/L (nmol/L)		
Reagent pipetting		Diluent (H ₂ O)	
R1	124 μ L	-	
R3	124 μ L	-	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	2 μ L	-	-
Decreased	2 μ L	10 μ L	100 μ L
Increased	2 μ L	-	-

Calibration

Calibrators	S1: H ₂ O S2: Calibrator β 2-Microglobulin
Calibration mode	Linear
Calibration frequency	2-point calibration - after reagent lot change - as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the WHO standard.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factor: mg/L x 84.7 = nmol/L

Limitations - interference

Criterion: Recovery within \pm 0.1 mg/L (8.47 nmol/L) of initial values at a β 2-microglobulin concentration of \leq 1.0 mg/L (84.7 nmol/L) and within \pm 10 % for samples $>$ 1.0 mg/L.

Hemolysis: No significant interference up to a hemoglobin concentration of 1100 mg/dL.¹¹

High dose hook-effect: No false result occurs up to a B2MG concentration of 240 mg/L (20328 nmol/L).

Drugs: No interference was found at therapeutic concentrations using common drug panels.¹²

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹³

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is required in certain cases. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SmpCln1+2/SCCS Method Sheet and for further instructions refer to the operator's manual.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges**Measuring range**

0.2-5.8 mg/L (16.9-491 nmol/L)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:11 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 11.

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 0.1 mg/L (8.5 nmol/L)

Limit of Detection = 0.15 mg/L (12.7 nmol/L)

Limit of Quantitation = 0.2 mg/L (16.9 nmol/L)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 20 %. It has been determined using low concentration human β 2-microglobulin samples.

Expected values

B2MG (urine), male: \leq 0.300 mg/L (25.4 nmol/L)¹⁴

B2MG (urine), female: \leq 0.183 mg/L (15.5 nmol/L)¹⁴

B2MG/creatinine (urine): \leq 0.029 mg/mmol¹⁴

24 h urine: 33-363 μ g¹⁰

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Tina-quant β 2-Microglobulin (urine application)**Precision**

Repeatability and intermediate precision were determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements (4 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Repeatability	Mean	SD	CV
	mg/L (nmol/L)	mg/L (nmol/L)	%
Control 1	2.51 (213)	0.0282 (2.39)	1.1
Control 2	5.45 (462)	0.121 (10.2)	2.2
Human urine 1	0.269 (22.8)	0.0135 (1.14)	5.0
Human urine 2	0.346 (29.3)	0.0140 (1.19)	4.0
Human urine 3	0.825 (69.9)	0.0194 (1.64)	2.4
Human urine 4	2.86 (242)	0.104 (8.81)	3.6
Human urine 5	4.71 (399)	0.0470 (3.98)	1.0
Intermediate precision	Mean	SD	CV
	mg/L (nmol/L)	mg/L (nmol/L)	%
Control 1	2.51 (213)	0.0835 (7.07)	3.3
Control 2	5.45 (462)	0.301 (25.5)	5.5
Human urine 1	0.269 (22.8)	0.0193 (1.63)	7.2
Human urine 2	0.346 (29.3)	0.0271 (2.30)	7.8
Human urine 3	0.825 (69.9)	0.0557 (4.72)	6.8
Human urine 4	2.86 (242)	0.149 (12.6)	5.2
Human urine 5	4.71 (399)	0.187 (15.8)	4.0

Method comparison

β 2-Microglobulin values for human urine samples obtained on a Roche/Hitachi **cobas c** 701 analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi **cobas c** 501 analyzer (x).

Sample size (n) = 118

Passing/Bablok ¹⁵	Linear regression
$y = 0.967x - 0.001$ mg/L	$y = 0.959x + 0.015$ mg/L
$\tau = 0.978$	$r = 0.999$

The sample concentrations were between 0.210 and 5.76 mg/L (17.8 and 488 nmol/L).

References




- Kawata M, Parnes JR, Herzenberg LA. Transcriptional control of HLA-A,B,C antigen in human placental cytotrophoblast isolated using trophoblast- and HLA-specific monoclonal antibodies and the fluorescence-activated cell sorter. *J Exp Med* 1984 Sep;160(3):633-651.
- Thomas L. *Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results*. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft 1998;685-688.
- Stadius van Eps LW, Schardijn GH. Value of determination of beta2-microglobulin in toxic nephropathy and interstitial nephritis. *Wien Klin Wochenschr* 1984 Sep;96(18):673-678.
- Regeniter A, Freidank H, Dickenmann M, et al. Evaluation of proteinuria and GFR to diagnose and classify kidney disease: Systematic review and proof of concept. *Eur J Intern Med* 2009 Oct;20(6):556-561.
- Solano A, Lew SQ, Ing TS. Dent-Wrong disease and other rare causes of the Fanconi syndrome. *Clin Kidney J* 2014 Aug;7(4):344-347.
- K/DOQI. *Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification*. *Am J Kidney Dis* 2002;39.
- Oetting WS, Rogers TB, Krick TP, et al. Urinary beta2-microglobulin is associated with acute renal allograft rejection. *Am J Kidney Dis* 2006 May;47(5):898-904.
- Bernard AM, Vyskocil A, Lauwerys RR. Determination of b2-Microglobulin in Human Urine and Serum by Latex Immunoassay. *Clin Chem* 1981;27(6):832-837.
- European Confederation of Laboratory Medicine (ECLM). *European Urinalysis Guidelines*. *Scand J Clin Lab Invest* 2000;60:1-96.
- Schardijn G, Stadius van Eps LW, Swaak AJ, et al. Urinary beta2-microglobulin in upper and lower urinary-tract infections. *The Lancet* 1979 Apr;1(8120):805-807.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. *Ann Clin Biochem* 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. *Clin Chem Lab Med* 2007;45(9):1240-1243.
- Chan PC, Kulasingam V, Lem-Ragosnig B. Validating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurements. *Clin Biochem* 2012 Nov;45(16-17):1533-1535.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.


COBAS, COBAS C and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2020, Roche Diagnostics



 Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

 +800 5505 6606



Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336